Keyphrases
Pancreatic Cancer
100%
Immunogenic
100%
Nanocarriers
100%
Irinotecan
100%
Anti-PD-1
100%
Silicasome
100%
Chemoimmunotherapy
100%
High Mobility Group Box 1 (HMGB1)
40%
Immunotherapy Response
40%
Immunogenic Cell Death
40%
Pancreatic Ductal Adenocarcinoma
40%
Calreticulin
40%
Onivyde
40%
Immunophenotyping
20%
Improved Survival
20%
Tumor Growth
20%
Cancer Tumor
20%
Endoplasmic Reticulum Stress (ER stress)
20%
Programmed Death-ligand 1 (PD-L1)
20%
Vaccination
20%
Pancreatic Cancer Cells
20%
Cancer Model
20%
Tumor Immunity
20%
Autophagy Inhibition
20%
Autophagy Markers
20%
Perforin
20%
Orthotopic Model
20%
Mesoporous Silica Nanoparticles
20%
Prolonged Life
20%
Pancreatic Duct Cells
20%
Lipid Bilayer
20%
Lysosomal pH
20%
Granzyme B
20%
Liposomal Drugs
20%
Programmed Death-ligand 1 Expression
20%
Survival Improvement
20%
Medicine and Dentistry
Pancreas Cancer
100%
Nanocarrier
100%
Chemoimmunotherapy
100%
Irinotecan
100%
Pancreas Adenocarcinoma
60%
Autophagy
40%
Programmed Death 1 Ligand 1
40%
Immunogenic Cell Death
40%
Irinotecan Sucrosofate
40%
Calreticulin
40%
Immunotherapy Response
40%
Cancer Cell
20%
Tumor Progression
20%
Contralateral
20%
Endoplasmic Reticulum Stress
20%
Life Sustaining Treatment
20%
Mesoporous Silica Nanoparticle
20%
Perforin
20%
Immunophenotyping
20%
Granzyme B
20%
Lipid Bilayer
20%
Pharmacology, Toxicology and Pharmaceutical Science
Nanocarrier
100%
Pancreas Cancer
100%
Irinotecan
100%
Immunotherapy
100%
Pancreas Adenocarcinoma
60%
Immunogenic Cell Death
40%
Programmed Death 1 Ligand 1
40%
Irinotecan Sucrosofate
40%
Calreticulin
40%
Tumor Growth
20%
Mesoporous Silica Nanoparticle
20%
Perforin
20%
Granzyme B
20%